FDA Approves New Drug for Bladder Cancer
May 19, 2016
The FDA has granted accelerated approval to atezolizumab (Tecentriq) for the treatment of locally advanced or metastatic urothelial carcinoma—the most common type of bladder cancer.
Anna Azvolinsky
CD4 T-Cell Immunotherapy Active in Various Cancers
April 19, 2016
Results of a trial involving a CD4-based immunotherapy has shown activity in patients with metastatic solid tumors, according to phase I data presented at the AACR Annual Meeting.
PTEN Mutation Status Potential Biomarker for Endometrial Cancer Therapies
March 25, 2016
Loss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.
DNA Methylation Signature Found in Common to Several Tumor Types
February 17, 2016
Detection of an epigenetic signature found in five different common tumor types—colon, lung, breast, stomach, and endometrial cancers—may be useful in diagnosing early-stage tumors using a blood test.
ASCO Issues Guideline on Biomarker-Based Adjuvant Breast Cancer Treatment
February 9, 2016
ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.
Pan-Mutation Test for Brain Tumors
February 9, 2016
Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.
Early-Stage Clinical Trials Underestimate Small Molecule, Targeted Anticancer Drug Toxicity
January 19, 2016
Dose-determining phase I clinical trials may not correctly determine the appropriate doses of small molecule oncology drugs to administer in larger, later stage trials.
Circulating Tumor DNA Analysis for Liquid Biopsies in Breast Cancer
December 18, 2015
We are speaking with Maximilian Diehn, MD, PhD, on developing genomics-based biomarkers to identify the presence of cancer cells for prognosis and predicting response to cancer therapies.
FDA Grants Crizotinib Priority Review in ROS1-Mutated Lung Cancer
December 16, 2015
The targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.
FDA Approves Alectinib for ALK-Positive NSCLC
December 14, 2015
On December 11, 2015, the US Food and Drug Administration (FDA) approved alectinib for patients with ALK-rearrangement positive non-small cell lung cancer (NSCLC) that is refractory to another ALK-targeted oral drug, crizotinib.
